Clincosm LogoSign in Get a demo

ANOPEC3: Circulating Endothelial Progenitor Cells and Aortic Aneurysm

Sponsor
Hopital Jean Minjoz (Other)
Overall Status
Unknown status
CT.gov ID
NCT01918982
Collaborator
(none)
40
Enrollment
31
Duration (Months)

Study Details

Study Description

Brief Summary

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm >30mm and <50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    40 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm
    Study Start Date :
    Oct 1, 2013
    Anticipated Primary Completion Date :
    Feb 1, 2016
    Anticipated Study Completion Date :
    May 1, 2016

    Arms and Interventions

    Arm Intervention/Treatment
    Aortic aneurysm

    Patients with aortic aneurysm >30mm and < 50mm

    Outcome Measures

    Primary Outcome Measures

    1. Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration [2 years]

      Patients are followed for 2 years

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Aortic aneurysm size >30mm and > 50mm
    Exclusion Criteria:

    • Infectious disease

    • Inflammatory disease

    • Liver insuffisency

    • Cancer evolutive

    • Pregnant women

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Hopital Jean Minjoz

    Investigators

    • Principal Investigator: Sidney Chocron, MD, PhD, Université de Franche-comté. France
    • Principal Investigator: Andrea Perrotti, MD, Université de Franche-Comté. France
    • Principal Investigator: Simon Rinckenbach, MD, PhD, Université de Franche-Comté. France
    • Principal Investigator: Siamak Davani, MD, PhD, Université de Franche-Comté. France

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Prof. Sidney Chocron, MD, PhD, Hopital Jean Minjoz
    ClinicalTrials.gov Identifier:
    NCT01918982
    Other Study ID Numbers:
    • 147/362
    First Posted:
    Aug 8, 2013
    Last Update Posted:
    Aug 8, 2013
    Last Verified:
    Aug 1, 2013
    Keywords provided by Prof. Sidney Chocron, MD, PhD, Hopital Jean Minjoz
    Aortic aneurysm
    circulating endothelial progenitor cells
    Additional relevant MeSH terms:
    Aneurysm
    Aortic Aneurysm

    Study Results

    No Results Posted as of Aug 8, 2013